Related Experiment Video
Updated: May 10, 2026
08:23
Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds
Published on: February 16, 2022
Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension
James R Klinger1, Steven H Abman, Mark T Gladwin
11 Division of Pulmonary, Sleep, and Critical Care Medicine, Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island.
Summary
Nitric oxide (NO) signaling is crucial in pulmonary circulation. Understanding NO
Area of Science:
- Cardiovascular Physiology
- Pulmonary Circulation Biology
- Vascular Medicine
Background:
- Nitric oxide (NO) signaling significantly influences vascular tone and remodeling in the pulmonary circulation.
- Abnormalities in NO synthesis and signaling are observed in pulmonary hypertension (PH) models and human patients.
- The precise role of NO signaling alterations in PH pathogenesis remains incompletely understood.
Purpose of the Study:
- To examine the current understanding of altered nitric oxide (NO) signaling in pulmonary hypertensive diseases.
- To discuss the contribution of NO signaling alterations to the pathogenesis of pulmonary hypertension.
- To review current and investigational therapies targeting NO signaling for pulmonary hypertension.
Main Methods:
- Review of existing literature on nitric oxide (NO) signaling in pulmonary vascular diseases.
- Analysis of data from animal models and human studies of pulmonary hypertension.
- Evaluation of the efficacy and limitations of NO-targeted therapies for pulmonary hypertension.
Main Results:
- Numerous abnormalities in NO synthesis and signaling are linked to pulmonary hypertension.
- It remains unclear whether these NO alterations are causative or reflective of the disease.
- Current therapies targeting NO signaling show variable efficacy in treating pulmonary hypertension.
Conclusions:
- Altered nitric oxide (NO) signaling is a significant feature of pulmonary hypertensive diseases.
- Further research is needed to elucidate the causal role of NO alterations in PH pathogenesis.
- NO-targeted therapies offer potential but require further development for effective PH reversal.
Related Concept Videos
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:30Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...